Drug · CHEMBL225072
PEMETREXED
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PEMETREXED. Drugs and targets, record CHEMBL225072. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL225072
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 99 diseases, from ATC, ClinicalTrials.gov, EMA Human Drugs, FDA and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DHFR | Dihydrofolate reductase | Dihydrofolate reductase inhibitor | INHIBITOR | https://conductscience.org/library/genes/1719 |
| GART | Trifunctional purine biosynthetic protein adenosine-3 | GAR transformylase inhibitor | INHIBITOR | https://conductscience.org/library/genes/2618 |
| TYMS | Thymidylate synthase | Thymidylate synthase inhibitor | INHIBITOR | https://conductscience.org/library/genes/7298 |
Source ChEMBL
Diseases99
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| non-small cell lung carcinoma | Approval | EMA Human Drugs | 647 | 633 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| malignant pleural mesothelioma | Approval | ClinicalTrials.gov, FDA and TTD | 40 | 38 | https://conductscience.org/library/drugs?q=MONDO_0005112 |
| leptomeningeal metastasis | Phase 2 | ClinicalTrials.gov | 25 | 25 | https://conductscience.org/library/drugs?q=EFO_1001012 |
| non-small cell squamous lung carcinoma | Phase 3 | ClinicalTrials.gov | 24 | 24 | https://conductscience.org/library/drugs?q=MONDO_0056806 |
| lung adenocarcinoma | Phase 3 | ClinicalTrials.gov | 23 | 23 | https://conductscience.org/library/drugs?q=MONDO_0005061 |
| breast cancer | Phase 2 | ClinicalTrials.gov | 20 | 20 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| lung cancer | Phase 3 | ClinicalTrials.gov | 20 | 20 | https://conductscience.org/library/drugs?q=MONDO_0008903 |
| colorectal cancer | Phase 2 | ClinicalTrials.gov | 18 | 18 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| mesothelioma | Approval | EMA Human Drugs | 28 | 14 | https://conductscience.org/library/drugs?q=MONDO_0005065 |
| small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
1 to 10 of 99Source Open Targets
See all 99 diseasesTrials933
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Phase 3 | 1,214 | 2023-01-04 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT03164616 | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). | Phase 3 | 1,186 | 2022-04-07 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT03976323 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | Phase 3 | 1,003 | 2025-02-06 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT00095199 | Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer | Phase 3 | 939 | 2012-10-15 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT00762034 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | Phase 3 | 939 | 2013-11-28 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | Phase 3 | 939 | 2011-07-18 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT00363415 | Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer | Phase 3 | 908 | 2009-10-06 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT02723955 | Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | Phase 1 | 829 | 2024-12-27 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT03425643 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Phase 3 | 797 | 2024-09-19 | pemetrexed | Its name | ClinicalTrials.gov |
| NCT00415194 | A Study for Patients With Head and Neck Cancer | Phase 3 | 795 | 2011-04-06 | pemetrexed | Its name | ClinicalTrials.gov |
1 to 10 of 933
See all 933 trialsComparisons in its trials181
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pem/Carbo/Bev vs Pac/Carbo/Bev: Number of Participants Receiving Concomitant Medication | 406 of 472 | 421 of 467 | 939 | NCT00762034 | Trial comparisons |
| Pem/Carbo/Bev vs Pac/Carbo/Bev: Number of Participants Who Received a Transfusion | 116 of 442 | 44 of 443 | 885 | NCT00762034 | Trial comparisons |
| Pem/Carbo/Bev vs Pac/Carbo/Bev: serious adverse events | 188 of 442 | 181 of 443 | 885 | NCT00762034 | Trial comparisons |
| Pembro + Chemo/Pembro vs Placebo + Chemo/Placebo: deaths from any cause | 110 of 397 | 144 of 400 | 797 | NCT03425643 | Trial comparisons |
| Pembro + Chemo/Pembro vs Placebo + Chemo/Placebo: serious adverse events | 165 of 396 | 133 of 399 | 795 | NCT03425643 | Trial comparisons |
| Pemetrexed/Cisplatin vs Placebo/Cisplatin: serious adverse events | 185 of 392 | 132 of 385 | 777 | NCT00415194 | Trial comparisons |
Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib vs Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo: Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 127 of 373 | 92 of 372 | 745 | NCT03829319 | Trial comparisons |
| Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib vs Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo: Part 2: Number of Participants Who Experienced an Adverse Event (AE) | 372 of 373 | 370 of 372 | 745 | NCT03829319 | Trial comparisons |
| MK-7684A + Chemotherapy vs Pembrolizumab + Chemotherapy: deaths from any cause | 190 of 366 | 193 of 373 | 739 | NCT05226598 | Trial comparisons |
| MK-7684A + Chemotherapy vs Pembrolizumab + Chemotherapy: serious adverse events | 205 of 360 | 180 of 368 | 728 | NCT05226598 | Trial comparisons |
1 to 10 of 181
See all 181 comparisons in its trialsPapers from its trials579
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials8
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 3 | 0 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Hidden Path Learning | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 0 | ConductCognition |
| Paired Associate Learning | 1 | 0 | ConductCognition |
| Symbol Scan Task | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL225072
GET https://conductscience.org/api/drugs/v1/CHEMBL225072/diseases?page=2